ROBERGE, MICHEL,MCMASTER, CHRIS,ZIMMERMAN, CARLA,POON, PAK
申请号：
CA2945196
公开号：
CA2945196A1
申请日:
2015.04.10
申请国别(地区):
CA
年份:
2015
代理人:
摘要：
Methods are provided for the treatment of Parkinson's disease (PD) in patients bearing mutations in the LRRK2 gene. A therapeutically effective amount of piperazine derivative compounds are employed to inhibit the biological activity of ArfGAP1, inhibition that counteracts the deleterious effects of mutations in, or increased expression of, the LRRK2 protein.
